TEVA Teva Pharma Industries Ltd ADR

$19.96

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 10/6/2025

About Teva Pharma Industries Ltd ADR

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Website: https://www.tevapharm.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
818686
Address
5 BAZEL ST, P O B 3190, PETACH TIKVA, IL
Valuation
Market Cap
$15.66B
P/E Ratio
nan
PEG Ratio
1.29
Price to Book
2.91
Performance
EPS
$-1.45
Dividend Yield
Profit Margin
-9.91%
ROE
-28.30%
Technicals
50D MA
$15.65
200D MA
$17.61
52W High
$22.80
52W Low
$12.46
Fundamentals
Shares Outstanding
1B
Target Price
$22.88
Beta
0.72

TEVA EPS Estimates vs Actual

Estimated
Actual

TEVA News & Sentiment

Oct 06, 2025 • GlobeNewswire NEUTRAL
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® ( omalizumab ) , Accepted by the European Medicines Agency
LONDON, UK and REYKJAVIK, ICELAND ( OCTOBER 6, 2025 ) - Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech ( NASDAQ: ALVO ) , a global biotech company ...
Oct 06, 2025 • GlobeNewswire NEUTRAL
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® ( omalizumab ) , Accepted by the European Medicines Agency
LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech ( NASDAQ: ALVO ) , a global ...
Oct 06, 2025 • Benzinga NEUTRAL
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® ( omalizumab ) , Accepted by the European Medicines Agency - Alvotech ( NASDAQ:ALVO )
LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech ( NASDAQ:ALVO ) , a global ...
Oct 06, 2025 • Motley Fool SOMEWHAT-BULLISH
Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters
Duquesne Family Office's billionaire boss bid adieu to Wall Street's hottest AI stocks in favor of another trillion-dollar company and a long-awaited turnaround story in the healthcare sector.
Sep 30, 2025 • Benzinga SOMEWHAT-BULLISH
Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus - Teva Pharmaceutical Indus ( NYSE:TEVA )
Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus ( NYSE:TEVA ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we ...
Sep 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Why Teva Pharmaceutical Industries Ltd. ( TEVA ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sentiment Snapshot

Average Sentiment Score:

0.137
50 articles with scored sentiment

Overall Sentiment:

Neutral

TEVA Reported Earnings

Jan 29, 2025
Dec 31, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $0.71
  • Estimate: $0.70
  • Whisper:
  • Surprise %: 1.1%
Nov 06, 2024
Sep 30, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $0.69
  • Estimate: $0.65
  • Whisper:
  • Surprise %: 6.2%
Jul 31, 2024
Jun 30, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $0.61
  • Estimate: $0.55
  • Whisper:
  • Surprise %: 10.9%
May 08, 2024
Mar 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $0.48
  • Estimate: $0.51
  • Whisper:
  • Surprise %: -5.9%
Jan 31, 2024
Dec 31, 2023 (Pre market)
0.23 Surprise
  • Reported EPS: $1.00
  • Estimate: $0.77
  • Whisper:
  • Surprise %: 29.9%
Nov 08, 2023
Sep 30, 2023 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.60
  • Estimate: $0.61
  • Whisper:
  • Surprise %: -1.6%
Aug 02, 2023
Jun 30, 2023 (Pre market)
0.03 Surprise
  • Reported EPS: $0.56
  • Estimate: $0.53
  • Whisper:
  • Surprise %: 5.7%
May 10, 2023
Mar 31, 2023 (Pre market)
-0.16 Surprise
  • Reported EPS: $0.40
  • Estimate: $0.56
  • Whisper:
  • Surprise %: -28.6%
Feb 08, 2023
Dec 31, 2022 (Pre market)
0.0 Surprise
  • Reported EPS: $0.71
  • Estimate: $0.71
  • Whisper:
  • Surprise %: 0.0%

Financials